



2016

# VARIANCE OF THE AMYLOID BETA PEPTIDE AS A METRIC FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE

Christina Beckett

*University of Kentucky*, [tinalbeckett@hotmail.com](mailto:tinalbeckett@hotmail.com)

Digital Object Identifier: <http://dx.doi.org/10.13023/ETD.2016.161>

**Right click to open a feedback form in a new tab to let us know how this document benefits you.**

---

## Recommended Citation

Beckett, Christina, "VARIANCE OF THE AMYLOID BETA PEPTIDE AS A METRIC FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE" (2016). *Theses and Dissertations--Medical Sciences*. 6.  
[https://uknowledge.uky.edu/medsci\\_etds/6](https://uknowledge.uky.edu/medsci_etds/6)

This Master's Thesis is brought to you for free and open access by the Medical Sciences at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Medical Sciences by an authorized administrator of UKnowledge. For more information, please contact [UKnowledge@lsv.uky.edu](mailto:UKnowledge@lsv.uky.edu).

**STUDENT AGREEMENT:**

I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File.

I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless an embargo applies.

I retain all other ownership rights to the copyright of my work. I also retain the right to use in future works (such as articles or books) all or part of my work. I understand that I am free to register the copyright to my work.

**REVIEW, APPROVAL AND ACCEPTANCE**

The document mentioned above has been reviewed and accepted by the student's advisor, on behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of the program; we verify that this is the final, approved version of the student's thesis including all changes required by the advisory committee. The undersigned agree to abide by the statements above.

Christina Beckett, Student

Dr. M. Paul Murphy, Major Professor

Dr. Joe Springer, Director of Graduate Studies

---

VARIANCE OF THE AMYLOID BETA PEPTIDE AS A METRIC FOR THE  
DIAGNOSIS OF ALZHEIMER'S DISEASE

---

THESIS

---

A thesis submitted in partial fulfillment of the  
requirements for the degree of Master of Science  
in the College of Medicine  
at the University of Kentucky

By

Christina Lisa Beckett

Lexington, Kentucky

Director: Dr. M. Paul Murphy, Molecular and Cellular Biochemistry

Lexington, Kentucky

Copyright © Christina L. Beckett 2016

## Abstract of Thesis

### VARIANCE OF THE AMYLOID BETA PEPTIDE AS A METRIC FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder associated with aging. AD is by far the best understood and most studied neurodegenerative disease. Substantial advances have been made over the last decade, however it is debatable how much closer we are to a clinically useful therapy. A long standing goal in the AD field has been to improve the accuracy of early detection, with the assumption that the ability to intervene earlier in the disease process will lead to a better clinical outcome. Major facets of this effort have been the continued development and improvement of AD biomarkers, with a strong focus on developing imaging modalities. AD is accompanied by two pathological hallmarks in the brain: extracellular neuritic plaques composed of the beta-amyloid peptide ( $A\beta$ ) and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein. Evidence of  $A\beta$  as the driving force behind the progression of AD (the amyloid cascade hypothesis) was first published by Hardy & Higgins in 1992, and this peptide has been the focus of therapeutic and diagnostic testing for decades. Significant technological advances in recent years now allow imaging of amyloid pathology *in vivo*. These methods evaluate  $A\beta$  burden in a living person, and could potentially serve as both a biomarker, and as a diagnostic tool to detect disease. Pittsburgh Compound B (PiB) is currently the best studied of these imaging agents, however, our current knowledge of the quantitative relationship between PiB binding and amyloid pathology in the brain is limited. A better understanding of how these variables relate to one another is essential for the continued development of reliable diagnostic biomarkers for AD. We analyzed increasingly insoluble pools of  $A\beta$  to quantify their relative contributions to the overall  $A\beta$  burden, and to determine if any of these measures could be used to predict disease status. We found that the amount of PiB binding in a cortical region of the brain could distinguish cases of mild cognitive impairment (MCI) when corrected to the amount of PiB binding in the cerebellum. As the  $A\beta$  peptide ages, the amino acid aspartate may spontaneously convert to an isoaspartate residue through a succinimide intermediary. The presence of iso-Asp  $A\beta$  has been used to indicate the presence of aged plaques in AD and Down syndrome cases. We sought to investigate the potential relationship between levels of 'aged'  $A\beta$  in the plasma as indicated by iso-Asp  $A\beta$  and disease state, as a potential biomarker for the presence of AD pathology. We found that AD cases had lower levels of all forms of  $A\beta$  in plasma when standardized to the group average, and that plasma levels of  $A\beta$  and iso-Asp  $A\beta$  were reversed between disease groups. A follow up study is required, however, these initial data are a promising step towards utilizing aged iso-Asp  $A\beta$  plasma levels as a potential biomarker to indicate disease state.

KEYWORDS: Alzheimer's Disease,  $A\beta$ , PiB, Isoaspartate, Biomarker

Christina Lisa Beckett  
Student Signature

April 27<sup>th</sup> 2016  
Date

VARIANCE OF THE AMYLOID BETA PEPTIDE AS A METRIC FOR THE  
DIAGNOSIS OF ALZHEIMER'S DISEASE

By

Christina Lisa Beckett

Dr. M. Paul Murphy  
Director of Thesis

Dr. Joe Springer  
Director of Graduate Studies

April 27<sup>th</sup> 2016  
Date

**To my fellow disasters....**

**...you know who you are.**

## ACKNOWLEDGEMENTS

My project would not have been possible without the samples I received from the Alzheimer's Disease Center at the Sanders-Brown Center on Aging. First and foremost, I must thank the participants who donated their bodies to science, and their families for supporting their decision. It is this type of altruistic giving that helps move the field forward and much of our research would not be possible without it.

I would like to thank the past and present members of the Murphy lab – you've made the lab a great place to work and do research, and have been fantastic travelling companions to travel the world to attend (or skip!) conferences and find many adventures along the way. Thanks to my PI, Dr. Paul Murphy, for being a great mentor and boss, and for teaching me WAY more than I've ever wanted to know about American politics!

A huge thank you to my committee members, Dr. Liz Head and Dr. Donna Wilcock, for your helpful advice on my thesis, and for your insightful questions and comments during my defence. A special mention goes to Liz for asking me a crazy question about alligator brains, and making my defence a memorable experience!

The biggest thank you goes to my Mum & Dad – I couldn't have asked for better parents. You've always been there for me, and have been the most loving and supportive parents imaginable. Thanks for everything you've done for me. I'm looking forward to a huge Ulster fry when I move home!

I also want to thank my friends both back home in Canada, and down here in the States. I've been so lucky to have a group of Canucks that have been my connection to Canada during my time in the US, and although I've been away for over a decade (I'd like to point out that I was only working on my Master's degree for the last two years, not that whole time!), our friendship has never wavered. Ashley, Tara, Samantha, and Cathy – I don't know what I would do without

you! Without the awesome friends I've made here in the States, I would never have stayed as long as I have, or had nearly as much fun. Robin, Josh, Val, and Shaun – I don't know what I would have done without you either! You bunch have been the best part of my living in the States, and although I don't have as long a history with you as I do with the Canuck contingent, I know that we'll be lifelong friends. Otherwise, who else are we going to go on summer vacations with and drive up the side of mountains in tiny ridiculous cars?!

An extra special shout out has to go to Val, because were it not for her, I never would have decided to go to graduate school. Val – it's all your fault ;)



## TABLE OF CONTENTS

Acknowledgements.....	iii
List of Tables .....	vi
List of Figures .....	vii
Chapter 1: Introduction .....	1
Chapter 2: Materials and Methods.....	6
Human Subjects and Neuropathological Assessment .....	6
A $\beta$ Extractions .....	10
PiB Binding .....	10
A $\beta$ ELISAs.....	11
Iso-Asp7 Antibody Production and Screening .....	12
Iso-Asp7 A $\beta$ in Human Brain Samples .....	13
Iso-Asp7 A $\beta$ in Human Plasma Samples.....	13
Chapter 3: Results .....	16
Chapter 4: Discussion.....	27
Appendices.....	32
Appendix I: List of Abbreviations .....	32
Appendix II: A $\beta$ Sequences.....	34
References .....	35
Vita .....	41

LIST OF TABLES

Table 2.1 Case Set 1 ..... 7  
Table 2.2 Case Set 2 ..... 9  
Table 2.3 Case Set for Plasma Iso-Asp7 A $\beta$  Measures ..... 14  
Table 3.1 A $\beta$ 40 and A $\beta$ 42 Values (Uncorrected)..... 19

## LIST OF FIGURES

Figure 3.1 Soluble A $\beta$ , Oligomeric A $\beta$ , and Fibrillar A $\beta$ .....	17
Figure 3.2 Correcting PiB Binding Values to the Cerebellum Distinguishes MCI Cases.....	20
Figure 3.3 PiB Binding Correlates with Less Soluble Forms of A $\beta$ in the SMTG.....	22
Figure 3.4 SDS Soluble A $\beta$ Indicates Disease State .....	24
Figure 3.5 AD Cases Have Lower Standardized Levels of Plasma A $\beta$ Than Control Cases.....	25
Figure 3.6 Levels of A $\beta$ and Iso-Asp7 A $\beta$ Were Reversed Between Groups .....	26

## CHAPTER 1: INTRODUCTION

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder associated with aging. Worldwide, the current number of individuals with AD is about 24 million, but could reach more than 80 million by the year 2040 (Ferri et al., 2005). AD is by far the best understood and most studied neurodegenerative disease. Although substantial advances have been made over the last decade, it is debatable how much closer we are to a clinically useful therapy. A long standing goal in the AD field has been to improve the accuracy of early detection, with the assumption that the ability to intervene earlier in the disease process will lead to a better clinical outcome. Major facets of this effort have been the continued development and improvement of AD biomarkers (Petersen et al., 2010; Trojanowski et al., 2010), with a strong focus on developing imaging modalities (Klunk, 2011).

First described by Dr. Alois Alzheimer over one hundred years ago, AD is characterized by progressive cognitive and behavioural decline and dementia (Cipriani, Dolciotti, Picchi, & Bonuccelli, 2011). AD is accompanied by two pathological hallmarks in the brain: extracellular neuritic plaques composed of the beta-amyloid peptide (A $\beta$ ) and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein. Evidence of A $\beta$  as the driving force behind the progression of AD (the amyloid cascade hypothesis) was first published by Hardy & Higgins (Hardy & Higgins, 1992), and this peptide has been the focus of therapeutic and diagnostic testing for decades.

A $\beta$  is a product of proteolytic processing of the amyloid precursor protein (APP). APP is a single transmembrane domain protein which is expressed ubiquitously throughout the body. There are multiple pathways for the processing of APP – not all of which produce A $\beta$ . Approximately ~90% of APP is processed through the non-amyloidogenic pathway, in which the

initial cleavage event is performed by  $\alpha$ -secretase *within* the A $\beta$  region, in the portion of APP located outside the membrane. This releases a secreted APP fragment (sAPP- $\alpha$ ), and leaves behind a C-terminal fragment within the membrane (CTF- $\alpha$ ). The second cleavage event is performed by  $\gamma$ -secretase within the membrane-bound region, which releases a p3 fragment and the APP intracellular domain (AICD) which may play a role in transcriptional regulation (O'Brien & Wong, 2011). The remaining ~10% of APP processing occurs through the amyloidogenic pathway. This processing event is similar to the non-amyloidogenic pathway except that the initial cleavage event is performed by  $\beta$ -secretase. Cleavage by  $\beta$ -secretase (the active component of which is BACE1) occurs outside the membrane and releases a secreted APP fragment (sAPP- $\beta$ ), leaving behind the membrane-bound fragment (CTF- $\beta$ ). The second cleavage event is also performed by  $\gamma$ -secretase, this time releasing the A $\beta$  peptide and the AICD. Depending on the site at which  $\gamma$ -secretase performs the cleavage, there is variation in the length of A $\beta$  peptide produced. The majority (~90%) of  $\gamma$ -secretase cleavage produces the more soluble, 40-amino acid long A $\beta$  peptide (A $\beta$ 40). Approximately 5-10% of  $\gamma$ -secretase cleavage produces an A $\beta$  peptide which is 42 amino acids in length (A $\beta$ 42). The remaining cleavage events produce A $\beta$  of varying sizes, the next most common being the 38-amino acid long A $\beta$ 38 (~1% of A $\beta$  produced). The A $\beta$ 42 peptide is more aggregate-prone, and is the major A $\beta$  peptide species present in the neuritic plaques found in Alzheimer's disease brain (Ahmed et al., 2010).

Significant technological advances in recent years now allow imaging of amyloid pathology *in vivo*. These methods evaluate A $\beta$  burden in a living person, and could potentially serve as both a biomarker, and as a diagnostic tool to detect incipient disease (Jagust et al., 2009). Pittsburgh Compound B (PiB, 2-[4' -(Methylamino)phenyl]-6- hydroxybenzothiazole), a derivative of the amyloid dye Thioflavin T, (Wang et al., 2004) is currently the best studied of

these imaging agents. After labeling with  $^{11}\text{C}$  for PET imaging, increased PiB retention can be quantified in brain regions known to accumulate A $\beta$  deposits in AD patients (Klunk et al., 2004). The utility of PiB and other probes for determining how mild cognitive impairment (MCI) progresses to AD is being evaluated in a large, multicenter effort (Apostolova et al., 2010; Grimmer et al., 2009; Klunk et al., 2004). Despite progress in understanding the contribution of A $\beta$  to neuronal dysfunction and neurodegeneration, the lack of a detailed analysis of the interrelationship between A $\beta$  and the other common indices of AD pathology has hampered our understanding of the development and progression of the disease. For instance, our current knowledge of the quantitative relationship between PiB binding and amyloid pathology in the brain is limited (Bacskai et al., 2007; Ikonovic et al., 2008; Klunk et al., 2005; Klunk et al., 2003; Leinonen et al., 2008). A better understanding of how these variables relate to one another is essential for the continued development of reliable diagnostic biomarkers for AD. We analyzed increasingly insoluble pools of A $\beta$  to quantify their relative contributions to the overall A $\beta$  burden, and to determine if any of these measures could be used to predict disease status.

Alzheimer's disease is a progressive neurodegenerative disease, proceeding through several stages. Although the exact staging of the disease is still debated, there is almost certainly a preclinical or prodromal phase of the disease where some AD pathology is present in the absence of readily apparent clinical impairment (PCAD) (Price et al., 2009). After this stage, patients will pass through a state of mild cognitive impairment (MCI) (Petersen, 2004; Petersen et al., 2001) before progressing to early stage AD, defined by the presence of specific clinical features, including functional memory impairment. About twenty percent of otherwise cognitively normal elderly show PiB retention in one or more neocortical regions (Aizenstein et al., 2008), and this is associated with a risk of later cognitive decline, indicating the presence of a

possible stage of preclinical AD (Morris et al., 2009; Pike et al., 2007). Some of these cases can eventually be classified as amnesic MCI (Villemagne et al., 2008). About sixty percent of MCI patients show elevated PiB binding in some part of the neocortex (Kemppainen et al., 2007; Pike et al., 2007), and higher levels of PiB binding are associated with faster rates of cognitive decline, increased incidence of conversion to AD, and a greater degree of cerebral atrophy (Ewers et al., 2012; Koivunen et al., 2011).

The amino acid aspartate (present at positions 1, 7, and 23 in the human A $\beta$  sequence) readily undergoes isomerization to produce isoaspartate (iso-Asp) under physiological conditions (Ahmed et al., 2010; Shimizu, Matsuoka, & Shirasawa, 2005). The reaction occurs when aspartate spontaneously converts to a succinimide intermediate; the succinimide intermediate is subsequently hydrolyzed to produce iso-Asp (Shimizu, Watanabe, Ogawara, Mori, & Shirasawa, 2000). The isomerization of aspartate is not a permanent modification. Isoaspartate can be converted back to aspartate by the highly conserved enzyme, protein L-isoaspartyl methyltransferase (PIMT), which is responsible for the recognition and repair of isoaspartate residues (Chondrogianni et al., 2014). Iso-Asp residues accumulate in aged proteins *in vitro* under physiologic temperature and pH (Reissner & Aswad, 2003), and its presence in A $\beta$  peptides isolated from AD brains has been documented (Shimizu et al., 2005). The presence of predominantly (55.0%) iso-Asp at position 7 in A $\beta$  (iso-Asp7 A $\beta$ ) from neuritic plaques was first reported by Roher (Roher et al., 1993), with the suggestion that these structural alterations in peptide composition could have an influence on A $\beta$  deposition and/or clearance. The presence of aspartate at position 7 in A $\beta$  was subsequently shown to be essential for classical complement pathway (CCP) activation; iso-Asp substitution at this position abolished the activation of the CCP (Velazquez, Cribbs, Poulos, & Tenner, 1997) indicating the significance of

modification to iso-Asp7 A $\beta$ . The presence of iso-Asp7 A $\beta$  has been used to indicate the presence of aged plaques in AD cases, and also in Down syndrome - a disorder which is also associated with the accumulation and deposition of the A $\beta$  peptide within the brain, due to the presence of an extra copy of APP-containing chromosome 21 and resultant higher production of the A $\beta$  peptide (Fonseca, Head, Velazquez, Cotman, & Tenner, 1999). Low levels of A $\beta$  peptide are detectable in human plasma samples, however, although A $\beta$  deposition in brain is a component of AD pathology, the presence of A $\beta$  in plasma is not indicative of the presence or severity of A $\beta$  plaques in the brain. We sought to investigate a potential relationship between levels of 'aged' A $\beta$  in the plasma as indicated by iso-Asp7 A $\beta$  and disease state, as a potential biomarker for the presence of AD pathology.



## CHAPTER 2: MATERIALS AND METHODS

### *Human Subjects and Neuropathological Assessment*

Samples were obtained from the tissue repository at the Alzheimer's Disease Center at the University of Kentucky Sanders-Brown Center on Aging (UK SBCoA). Details of the recruitment, inclusion criteria, and mental status test batteries have been described previously (Schmitt et al., 2000). Diagnoses followed the National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease (Hyman et al., 2012). Human tissue collection and handling followed PHS guidelines and the University of Kentucky IRB.

Cases used for set one of the PiB binding measures (Table 2.1) were as follows: control cases (n = 9, 5M / 4F; age,  $84.3 \pm 5.1$  years) had no history of antemortem cognitive impairment (MMSE:  $28.4 \pm 1.5$ ; last MMSE:  $0.7 \pm 0.4$  years); AD cases (n = 10, 4M / 6F; age,  $83.4 \pm 5.7$  years) showed substantial cognitive impairment (MMSE,  $9.9 \pm 6.0$ ; last MMSE:  $2.4 \pm 2.3$  years). Prodromal or preclinical AD (PCAD) cases (n = 10, 1M / 9F; age,  $85.6 \pm 3.7$  years) were defined as those that met the NIA-Reagan neuropathology criteria for likely AD, but exhibited no clinical signs of dementia (MMSE,  $29.4 \pm 0.7$ ; last MMSE:  $0.8 \pm 0.5$  years) (Price et al., 2009). Amnesic MCI cases (n = 7, 3M / 4F; age,  $89.0 \pm 5.8$  years) were defined as per Petersen et. al. (Petersen et al., 1999); MMSE scores ( $24.8 \pm 3.1$ ; last MMSE:  $0.6 \pm 0.3$  years) were significantly lower ( $p < 0.04$ ) in this group compared to the control group. Frontotemporal dementia (FTD) cases (n = 6, 3M / 3F; age,  $61.0 \pm 14.6$  years) were included as an additional neurodegenerative disease and served as a specificity control (Cairns et al., 2007). FTD, which typically occurs at a younger age than AD, results in a significant cognitive impairment (MMSE,  $7.8 \pm 9.0$ ;  $p < 0.001$ ; last MMSE:  $4.6 \pm 3.1$

**TABLE 2.1: Case Set 1, PiB Binding**

<b>DISEASE STATE</b>	<b>n</b>	<b>AGE (yrs)</b>	<b>MMSE</b>
CONTROL (CON)	9 (5M/4F)	84.3 ± 5.1	28.4 ± 1.5
PRECLINICAL AD (PCAD)	10 (1M/9F)	85.6 ± 3.7	29.4 ± 0.7
AMNESTIC MILD COGNITIVE IMPAIRMENT (MCI)	7 (3M/4F)	89.0 ± 5.8	24.8 ± 3.1
ALZHEIMER'S DISEASE (AD)	10 (4M/6F)	83.4 ± 5.7	9.9 ± 6.0
FRONTOTEMPORAL DEMENTIA (FTD)	6 (3M/3F)	61.0 ± 14.6	7.8 ± 9.0

*Brain regions: superior and middle temporal gyri (SMTG), cerebellum (CB)*

years) but does not typically show the same pattern of neuropathology as AD. A $\beta$  deposition is not a feature of FTD (Cairns et al., 2007).

Cases for set two of the PiB binding experiments (Table 2.2) were as follows: control cases (N = 23; 87.0  $\pm$  6.5 years) had no history of antemortem cognitive impairment and were age-matched to AD cases (N = 22; 85.8  $\pm$  7.6 years). The average postmortem interval (PMI) was similar for both groups (Control: 3.0  $\pm$  0.8; AD: 2.9  $\pm$  0.7, hours).

Brain weights were determined and a gross neuropathological evaluation carried out at the time of autopsy. Tissue samples were dissected and frozen or formalin fixed. For histology, paraffin-embedded specimens were cut (8  $\mu$ m) and stained with standard hematoxylin-eosin, modified Bielschowsky method, or Gallyas silver method. Braak staging (Braak & Braak, 1991) used both Gallyas and Bielschowsky-stained sections. Neurofibrillary tangles (NFTs), diffuse plaques (DPs; plaques without surrounding dystrophic, argyrophilic neurites), and neuritic plaques (NPs; plaques surrounded by dystrophic, argyrophilic neurites) were counted and averaged as described (Markesbery et al., 2006; Nelson et al., 2010; Nelson et al., 2007). There was no cause of death pattern in any disease group.

**TABLE 2.2: Case Set 2**

<b>DISEASE STATE</b>	<b>n</b>	<b>AGE (yrs)</b>	<b>MMSE</b>
CONTROL (CON)	23 (7M/16F)	87.0 ± 6.5	28.6 ± 1.4
ALZHEIMER'S DISEASE (AD)	22 (8M/14F)	85.8 ± 7.6	12.1 ± 8.1

*Brain regions: midfrontal gyri (BA9), superior and middle temporal gyri (SMTG), inferior parietal lobule (IP), hippocampal formation (HIP), cerebellum (CB)*

### ***A $\beta$ Extractions***

A $\beta$  was extracted from human brain samples under increasingly stringent conditions as described previously (Beckett et al., 2010). Briefly, frozen brain samples were weighed and homogenized via polytron in ice cold phosphate buffered saline (PBS, pH 7.4) including a complete protease inhibitor cocktail (PIC; Amresco, Solon, OH) at 200 mg/mL. An aliquot of raw homogenate was conserved for PiB binding measures; remaining raw homogenate was then centrifuged (20,800 x *g* for 30 mins @ 4°C), and the supernatant was collected. The pellets were re-extracted by sonication in 2% sodium dodecyl sulphate (SDS) with PIC (10 x 0.5 sec pulses @ 100 W; Fisher Sonic Dismembrator, Fisher Scientific, Pittsburgh, PA), centrifuged (20,800 x *g* for 30 mins @ 14°C), and the supernatant collected. Finally, the remaining pellet was re-extracted in 70% (v/v) formic acid followed by centrifugation (20,800 x *g* for 1 h @ 4°C), and collection of the supernatant. The extracts were stored at -80°C until time of assay.

### ***PiB Binding***

<sup>3</sup>H-PiB binding to brain homogenates was carried out similar to the filtration assay of Klunk et al. (Klunk et al., 2005), as per Rosen et al. (Rosen, Walker, & Levine, 2011). Briefly, unfractionated PBS homogenate was diluted into a 96-well polypropylene plate in triplicate. Two hundred  $\mu$ l of 1nM <sup>3</sup>H-PiB (custom synthesized by ViTrax Radiochemicals, Placentia, CA; a kind gift of Dr. Brian Ciliax, Emory University) was added to each of the first two wells, and 1  $\mu$ M of an unlabeled competitor (BTA-1) was added to the third well to determine nonspecific binding (by subtraction). Femtomoles of <sup>3</sup>H-PIB bound were calculated per wet weight of tissue after correcting for counting efficiency.

## **A $\beta$ ELISAs**

A $\beta$ 40 and A $\beta$ 42 were measured using a well-characterized sandwich ELISA, details of which have already been published (Beckett et al., 2010; Das et al., 2003; McGowan et al., 2005; Murphy et al., 2007; Weidner et al., 2011). Briefly, 384-well plates (Immulon microtiter 4 HBX; Thermo Scientific, Rochester, NY) were coated with a capture antibody at a concentration of 0.5  $\mu$ g/well, sealed, and incubated overnight @ 4°C. The following day, plates were washed once with PBS and blocked with 100  $\mu$ L of blocking buffer (Synblock; AbD Serotec, Raleigh, NC) according to manufacturer's directions. Blocked plates were sealed and stored, desiccated, @ 4°C until use. Prior to use, plates were washed twice with PBS and standards and samples were loaded at least in triplicate. A standard curve was prepared using synthetic A $\beta$  peptide (A $\beta$ 40 or A $\beta$ 42, as appropriate; rPeptide, Bogart, GA) diluted in antigen capture buffer (AC; 0.02 M sodium phosphate buffer (pH = 7), 0.4 M NaCl, 2 mM EDTA, 0.4% Block Ace (Serotec; Raleigh, NC), 0.2% BSA, 0.05% CHAPS, and 0.05% NaN<sub>3</sub>). Samples were diluted in AC buffer prior to loading (PBS samples were diluted 1:4, SDS samples were diluted ranging from 1:20 to 1:100). Formic acid samples were neutralized 1:20 in TP buffer (1 M Tris base, 0.5 M Na<sub>2</sub>HPO<sub>4</sub>), followed by a further dilution in AC buffer for final dilution ranging between 1:100 and 1:400. The capture antibody used for the A $\beta$ 40 measures was Ab42.5 (specific for human A $\beta$ 1-16), and the capture antibody for the A $\beta$ 42 measures was 2.1.3 (c-terminal specific for A $\beta$ 42). Detection was performed with biotinylated 13.1.1 (1:1000, c-terminal specific for A $\beta$ 40) or biotinylated 4G8 (1:2000, specific for A $\beta$ 17-24; BioLegend, San Diego, CA), followed by NeutrAvidin-HRP (1:5000; Thermo Fisher, Waltham, MA). Finally, plates were developed with 3,3',5,5'-tetramethylbenzidine (TMB; Kirkegaard and Perry Laboratories (KPL), Gaithersburg, MD), stopped with 6%  $\sigma$ -phosphoric acid, and read at 450 nm.

Oligomeric A $\beta$  was measured using a similar process, using the same antibody for both capture and detection (capture: 4G8 @ 0.1  $\mu$ g/well, detection: biotinylated-4G8 @ 1:2000; BioLegend) followed by NeutrAvidin-HRP. The plates were developed with TMB (KPL), stopped with 6%  $\sigma$ -phosphoric acid, and read at 450 nm.

### ***Iso-Asp7 Antibody Production and Screening***

Monoclonal antibodies directed against iso-Asp7 A $\beta$  were produced by abpro (Woburn, MA), and culture media from selected hybridomas were sent to our lab at UK for screening. Initial clones were screened for specificity via direct ELISA against iso-Asp7 A $\beta$ 1-16 and non-iso-Asp A $\beta$ 1-16. Immulon 4 HBX plates were coated with synthetic peptide (iso-Asp7 A $\beta$ 1-16 or non-iso-Asp A $\beta$ 1-16) @ 0.1  $\mu$ g/well and incubated overnight @ 4°C. The following day, plates were washed once with PBS and blocked with Synblock (100  $\mu$ L/well) for 1 hour @ room temperature. Next, the Synblock was removed and the plates were allowed to dry upside down for 1 hour at room temperature. The plates were then washed twice with PBS and the clonal supernatants were diluted into detection buffer (DB; 0.2 M sodium phosphate buffer (pH = 7), 2 mM EDTA, 0.4 M NaCl, 1% BSA, 0.002% thimerosal) to create a dilution series (no dilution, 1:10, 1:100, and 1:1000) and loaded at 100  $\mu$ L/well. The plates were sealed and incubated at room temperature for 1 hour. The plates were then washed twice with PBST (PBS with 0.5% Tween-20) and twice with PBS. The plates were then incubated with goat- $\alpha$ -mouse-IgG-HRP (1:20,000 in DB; Pierce, Rockford, IL) for 1 hour at room temperature. Finally, the plates were washed four times with PBST and four times with PBS. They were then developed with TMB (KPL), stopped with 6%  $\sigma$ -phosphoric acid, and read at 450 nm. The ODs from the iso-Asp7 A $\beta$  and the non-iso-Asp A $\beta$  conditions were compared to each other. The clones which were reactive to iso-Asp7 A $\beta$  and *not*

non-iso-Asp A $\beta$  were selected for further subcloning. A total of five clones were selected for subcloning.

The supernatants from the subclones were screened following the procedure as described above. Two of the subclones (3A9.H7 and 7C2.E12) which showed high specificity for iso-Asp7 A $\beta$  and non-reactivity to non-iso-Asp A $\beta$  were chosen to be scaled up for antibody production and purification. Antibody 7C2.E12 was chosen for use in the screening of human samples for iso-Asp7 A $\beta$  because it had a slightly better specificity profile than 3A9.H7.

#### ***Iso-Asp7 A $\beta$ in Human Brain Samples***

Serially extracted human brain samples from the inferior temporal region were screened for iso-Asp7 A $\beta$  reactivity via sandwich ELISA. Antibody 2.1.3 (c-terminal specific for A $\beta$ 42) was used as a capture antibody (0.5  $\mu$ g/well). PBS, SDS, and neutralized formic acid samples were loaded at appropriate dilutions in AC buffer (control samples: PBS @ 1:4, SDS @ 1:20, FA @ 1:100; AD samples: PBS @ 1:4, SDS @ 1:100, FA @ 1:400). Detection was performed using biotinylated antibodies 3A9.H7, 7C2.E12, or 6E10 (1:1000 in DB; 6E10 against human A $\beta$ 1-16; BioLegend), followed by NeutrAvidin-HRP @ 1:5000. The plates were then developed with TMB (KPL), stopped with 6%  $\sigma$ -phosphoric acid, and read at 450 nm.

#### ***Iso-Asp7 A $\beta$ in Human Plasma Samples***

Plasma from AD and control cases were received from the UK SBCoA Alzheimer's Disease Center (Table 2.3). Controls (N=10 4F/6M; 82.9  $\pm$  2.6 years) had no history of ante-mortem cognitive impairment and were age-matched to AD cases (N=10, 5F/5M; 85.6  $\pm$  1.7 years). The average postmortem interval (PMI) was similar for both groups (Control: 4.7  $\pm$  1.0; AD: 6.9  $\pm$  1.7, hours). A $\beta$ 40, A $\beta$ 42, iso-Asp7 A $\beta$ 40, and iso-Asp7 A $\beta$ 42 levels in plasma from AD



**TABLE 2.3: Case Set for Plasma Iso-Asp7 A $\beta$  Measures**


<b>DISEASE STATE</b>	<b>n</b>	<b>AGE (yrs)</b>	<b>MMSE</b>
CONTROL (CON)	10 (6M/4F)	82.9 $\pm$ 2.6	27.7 $\pm$ 0.8
ALZHEIMER'S DISEASE	10 (5M/5F)	85.6 $\pm$ 1.7	15.9 $\pm$ 3.1

*\*Note: In this case set, the average MMSE score was calculated from only 9 of the 10 AD cases, as the MMSE test was not able to be completed for one of the participants due to behavioral/cognitive problems.*

cases and controls were measured via sandwich ELISA. Both A $\beta$ 40 and iso-Asp7 A $\beta$ 40 were captured with antibody 13.1.1 (0.5  $\mu$ g/well, c-terminal specific for A $\beta$ 40); A $\beta$ 42 and iso-Asp7 A $\beta$ 42 were measured with capture antibody 2.1.3 (0.5  $\mu$ g/well, c-terminal specific for A $\beta$ 42). Non-isomerized A $\beta$  (both A $\beta$ 40 & A $\beta$ 42) was detected with biotinylated-6E10 (1:1000, specific for human A $\beta$ 1-16), and iso-Asp7 A $\beta$  (40 & 42) was detected with biotinylated-7C2.E12 (1:1000, specific for iso-Asp7 A $\beta$ 1-16) followed by NeutrAvidin-HRP (1:5000). Plates were then developed with TMB (KPL), stopped with 6%  $\sigma$ -phosphoric acid, and read at 450 nm. A standard curve was prepared using synthetic non-isomerized A $\beta$  (either A $\beta$ 40 or A $\beta$ 42, as appropriate) which was used to predict the values for the non-isomerized A $\beta$  conditions. For the iso-Asp7 A $\beta$  conditions, dilutions of synthetic iso-Asp7 A $\beta$ 1-16 were coated directly onto the plate, and were detected with biotinylated 7C2.E12.

### CHAPTER 3: RESULTS

For case set one, quantitative measurements of A $\beta$  by ELISA were performed from both SMTG and cerebellum (Figure 3.1). The total amount of A $\beta$  found in the disease cases was increased in both the SMTG (SDS: F[4,32] = 63.01, p<0.0001; FA: F[4,32] = 7.00, p<0.001) and cerebellum (SDS: F[4,31] = 11.49, p<0.001; FA: F[4,31] = 4.5, p<0.006). There were no disease-related differences between the amounts of aqueous (PBS) soluble A $\beta$  in either region (SMTG: F[4,32] = 1.39, n.s.; cerebellum: F[4,31] = 2.07, n.s.). The disease-related increase in the SMTG relative to the cerebellum was larger in the SDS fraction (F[4,29] = 32.37, p<0.0001) but not in the FA fraction (F[4,29] = 0.97, n.s.). The largest values were from the AD cases, with smaller increases observed in the PCAD and MCI cases. The PCAD and MCI groups were not significantly different from each other. There was ~8 times more SDS-soluble A $\beta$  in the SMTG compared to the cerebellum in the AD group as compared to the controls (t[9] = 6.77, p<0.01), whereas there was no difference between the amounts of FA-soluble A $\beta$  in the same cases (t[9] = -0.63, n.s.). Effects were similar for both A $\beta$ 40 and A $\beta$ 42 (Table 3.1). There was significantly more oligomeric A $\beta$  in the SMTG (F[4,32] = 5.00, p<0.003), but not in the cerebellum (F[4,31] = 1.15, n.s.), in disease. When compared to the cerebellum, oligomeric A $\beta$  was higher in the SMTG in the AD (t[9] = 7.09, p<0.01), PCAD (t[9] = 3.32, p<0.04), and MCI (t[5] = 4.03, p<0.03) cases. PiB binding was similarly elevated in the SMTG (F[4,32] = 7.08, p<0.001). PiB binding was minimal in the cerebellum, and did not show a strong disease-related increase (F[4,31] = 2.2, p<0.1) in this region. There were no significant differences between the FTD cases and controls.



**Figure 3.1 Soluble A $\beta$ , Oligomeric A $\beta$ , and Fibrillar A $\beta$ .**

Sandwich ELISA (soluble A $\beta$ ): The total amount of A $\beta$  was increased in AD in both the SMTG and cerebellum in the SDS and FA fractions; PBS-soluble A $\beta$  was not elevated in disease. Increases in PCAD and MCI cases were modest relative to controls, and were most apparent in the FA fraction isolated from the SMTG. FTD cases were essentially indistinguishable from control cases. Data shown are corrected for age and PMI. Similar results were obtained in separate evaluations of A $\beta$ 40 and A $\beta$ 42 (Table 3.1). Single-Site ELISA (oligomeric A $\beta$ ): Oligomeric A $\beta$  was only significantly higher in the SMTG and not within the cerebellum. Values for PCAD and MCI cases were intermediate between control and AD cases; FTD cases were slightly lower than controls, although this was not a significant difference. PiB Binding (fibrillary A $\beta$ ): Fibrillary A $\beta$ , as defined by PiB binding, was significantly higher in the SMTG than in the cerebellum. Values for PCAD and MCI cases were intermediate between control and AD cases; FTD cases were not significantly different from control cases and, similar to oligomeric A $\beta$ , were slightly lower. Dunnett's test, \* =  $p < 0.05$ , \*\* =  $p < 0.01$ . Reprinted from (Beckett et al., 2012) with permission from IOS Press.

Although we could detect clear differences in postmortem PiB binding between the SMTG and cerebellum, they were significant in the AD group ( $t[9] = 6.61$ ,  $p < 0.01$ ), but only marginally significant for the PCAD ( $t[9] = 2.60$ , unadjusted  $p < 0.03$ ) and MCI ( $t[5] = 2.84$ , unadjusted  $p < 0.04$ ) groups. For amyloid imaging *in vivo*, values for cortical PiB retention are typically standardized to values obtained from the cerebellum in the same patient [16]. We therefore performed a similar comparison in our case series, by standardizing the SMTG value to the cerebellum from the same case (Figure 3.2). Since the oligomeric A $\beta$  measures exhibited a pattern comparable to PiB binding, we did the same analysis in these cases. There were no differences between disease states when the amount of oligomeric A $\beta$  in the SMTG was standardized in this manner ( $F[4,31] = 0.86$ , n.s.). The postmortem PiB binding ratio was significantly different in disease when the SMTG values were corrected to the cerebellum ( $F[4,31] = 5.70$ ,  $p < 0.001$ ). When the data were analyzed in this way, the MCI group was notably higher than the other groups, an effect attributable to the very low levels of cerebellar PiB binding in this subgroup.

**TABLE 3.1: A $\beta$ <sub>40</sub> and A $\beta$ <sub>42</sub> Values (Uncorrected)**


	<b>SMTG</b>					
	<b>PBS</b>		<b>SDS</b>		<b>FA</b>	
	<b>A<math>\beta</math><sub>40</sub></b>	<b>A<math>\beta</math><sub>42</sub></b>	<b>A<math>\beta</math><sub>40</sub></b>	<b>A<math>\beta</math><sub>42</sub></b>	<b>A<math>\beta</math><sub>40</sub></b>	<b>A<math>\beta</math><sub>42</sub></b>
<b>CON</b>	0.3 ± 0.2	1.3 ± 0.3	4.9 ± 3.1	17.6 ± 9.1	10.1 ± 1.6	24.0 ± 19.2
<b>PCAD</b>	0.3 ± 0.1	1.6 ± 0.2	2.6 ± 0.9	19.8 ± 6.3	13.0 ± 1.3	44.0 ± 20.6
<b>MCI</b>	0.4 ± 0.1	1.2 ± 0.5	3.1 ± 0.6	16.0 ± 6.1	27.3 ± 4.1	116 ± 82.4
<b>AD</b>	0.6 ± 0.3	2.0 ± 0.3	111 ± 52.5*	1032 ± 131*	310 ± 108.3*	98.7 ± 16.5
<b>FTD</b>	0.3 ± 0.1	1.3 ± 0.6	3.1 ± 0.7	0.0 ± 0.0	18.0 ± 1.5	18.3 ± 19.2

	<b>Cerebellum</b>					
	<b>PBS</b>		<b>SDS</b>		<b>FA</b>	
	<b>A<math>\beta</math><sub>40</sub></b>	<b>A<math>\beta</math><sub>42</sub></b>	<b>A<math>\beta</math><sub>40</sub></b>	<b>A<math>\beta</math><sub>42</sub></b>	<b>A<math>\beta</math><sub>40</sub></b>	<b>A<math>\beta</math><sub>42</sub></b>
<b>CON</b>	0.2 ± 0.0	2.1 ± 0.2	7.9 ± 1.6	0.7 ± 0.7	12.2 ± 1.3	2.5 ± 2.5
<b>PCAD</b>	0.2 ± 0.1	1.6 ± 0.3	11.4 ± 0.9	0.2 ± 0.2	13.4 ± 1.2	2.2 ± 1.5
<b>MCI</b>	0.0 ± 0.0	0.8 ± 0.3	11.1 ± 0.9	1.2 ± 1.0	14.8 ± 3.0	0.0 ± 0.0
<b>AD</b>	0.4 ± 0.2	1.2 ± 0.3	53.8 ± 28.8	62.0 ± 5.3*	544 ± 328.7	87.9 ± 37.6*
<b>FTD</b>	0.0 ± 0.0	1.4 ± 0.1	7.3 ± 1.4	0.0 ± 0.0	9.0 ± 0.9	0.2 ± 0.2

Values are given in pmol / g (see main text for a description of the methods)

\*  $p < 0.05$ , Dunnett's test (relative to control group).




**Figure 3.2 Correcting PiB Binding Values to the Cerebellum Distinguishes MCI Cases.**

(A) There were no differences between disease states when the amount of oligomeric A $\beta$  in the SMTG was standardized to the amount found in the cerebellum. (B) There was a significant difference detected for disease when PiB binding in the SMTG was corrected to the amount in the cerebellum. Interestingly, the most prominent effect of this standardization was to amplify the difference between the MCI cases as compared to the other groups. Dunnett's test, \*\* =  $p < 0.01$ . Reprinted from (Beckett et al., 2012) with permission from IOS Press.

Finally, for this case series we wanted to determine how PiB binding related to other aspects of A $\beta$  pathology (Figure 3.3). Postmortem PiB binding was strongly correlated with the total plaque number ( $R^2 = 0.51$ ,  $p < 0.0001$ ; not shown). Whereas plaque counts are a reasonable means to determine disease status, it is likely that A $\beta$  positive area is a stronger correlate of PiB binding (Ikonomovic et al., 2008). Oligomeric A $\beta$  was only correlated with SDS soluble A $\beta$ 42 ( $R^2 = 0.16$ ,  $p < 0.01$ ; not shown). PiB binding was significantly correlated with both SDS- ( $p < 0.001$ ) and FA- ( $p < 0.05$ ) soluble A $\beta$ , but not with PBS-soluble A $\beta$  ( $p < 0.12$ ). These forms of the peptide are less soluble by definition (they require either a harsh detergent or acid to solubilize), and also show the most consistent increases with disease. In both cases, the strongest correlation was with A $\beta$ 42 (SDS:  $R^2 = 0.46$ ,  $p < 0.001$ ; FA:  $R^2 = 0.21$ ,  $p < 0.002$ ). PiB binding was also significantly correlated with the amount of oligomeric A $\beta$  ( $R^2 = 0.22$ ,  $p < 0.01$ ). PiB binding was not significantly correlated with any of these forms of A $\beta$  (including either A $\beta$ 40 or A $\beta$ 42) in the cerebellum (oligomeric A $\beta$ ,  $p < 0.3$ ; PBS-soluble A $\beta$ ,  $p < 0.4$ ; SDS-soluble A $\beta$ ,  $p < 0.15$ ; FA-soluble A $\beta$ ,  $p < 0.1$ ; data not shown). This was somewhat surprising, as at least two of these forms of A $\beta$  (SDS- and FA-soluble) did show significant changes in the cerebellum with disease, and were higher in the AD cases (Table 3.1; Figure 3.1). We did not detect a relationship ( $p < 0.5$ ) between any aspect of cerebrovascular pathology and postmortem PiB binding in this case series.

For the second case series, we determined which combination of A $\beta$  measurements best discriminated AD cases from controls. To this end, we used a logistic regression model for the presence of disease. We then used a stepwise procedure to identify the subset of measurements that best predicted that a randomly selected subject was an AD case (by log odds ratio). A simple solution was obtained, as there was only one variable in the best subset: the total amount of SDS soluble A $\beta$ , with an odds ratio of  $1.06 \pm 0.04$  (95 % C.I.). A box plot of the






**Figure 3.3 PiB Binding Correlates with Less Soluble Forms of A $\beta$  in the SMTG.**

(A) The amount of postmortem PiB binding was significantly correlated with oligomeric A $\beta$  ( $p < 0.01$ ). (B) PiB binding was not correlated with A $\beta$  extractable in PBS, the most soluble form of the peptide. However, PiB binding was significantly correlated with A $\beta$  extractable in either SDS (C;  $p < 0.001$ ) or FA (D;  $p < 0.05$ ). Reprinted from (Beckett et al., 2012) with permission from IOS Press.


same data showed minimal overlap between AD cases and controls (Figure 3.4). While informative, the overall sample size was too small to conduct a training-validation approach to selecting the best predictor of disease status. Although values between 90 and 95 could be used as a cut-off point to declare an individual to be an AD case, the data set was not large enough to identify a more precise number. PiB binding offered no discernible advantage as a diagnostic tool in this context.

To test the hypothesis that iso-Asp7 A $\beta$  might have predictive value in differentiating AD cases from controls, we evaluated a set of twenty cases from the UK ADC. For this study, we compared normal plasma A $\beta$ 40 and A $\beta$ 42 using our standard sandwich ELISA, alongside iso-Asp7 A $\beta$ 40 and iso-Asp7 A $\beta$ 42. In general, AD cases were lower on all forms of A $\beta$  when standardized to the group average (Figure 3.5), although only iso-Asp7 A $\beta$ 40 was close to significant on this measure ( $p < 0.06$ ). It is possible given the uniform direction of the trend that the data might better segregate given a larger sample size. The A $\beta$  values were highly variable in general (Figure 3.6). However, there was a potentially interesting crossover effect in the data. In this case, A $\beta$ 40 values in controls were lower than A $\beta$ 42, but reversed for iso-Asp7 (i.e., iso-Asp7 A $\beta$ 40 was higher than iso-Asp7 A $\beta$ 42). A somewhat similar effect was observed in the AD cases. We evaluated this change using a simple sign test. In this case, the change in direction in the A $\beta$ 40 values trended towards significance ( $p < 0.12$ ), but was significant for A $\beta$ 42 ( $p < 0.02$ ). However, although this is a promising outcome, there were not enough cases to determine if this could be used to distinguish AD cases from control cases. This will need to be determined in a larger, follow-up study.




**Figure 3.4 SDS Soluble A $\beta$  Indicates Disease State.**

SDS soluble A $\beta$  was identified as an exceptionally strong indicator of disease state. The area under the receiver operator curve was 0.978 ( $p = 0.0016$ ), with a sensitivity of 100% and a specificity of 95.7%. The Hosmer-Lemeshow goodness of fit statistic ( $p = 0.51$ ) indicated no evidence of a lack of fit. A boxplot of SDS soluble A $\beta$ , segregated by disease state, shows almost no overlap between cases and controls (A); PiB binding, in contrast, shows considerable overlap (B). Reprinted from (Niedowicz, Beckett, et al. 2012) with permission from John Wiley and Sons.



**Figure 3.5 AD Cases Have Lower Standardized Levels of Plasma A $\beta$  Than Control Cases.**

Levels of plasma A $\beta$  were measured from 20 human cases (Control: N=10, 6F/4M; 82.9  $\pm$  2.6 years; AD: N=10, 5F/5M; 85.6  $\pm$  1.7 years). When standardized to the group average, AD cases had lower levels plasma A $\beta$ , regardless of form. However, only iso-Asp7 A $\beta$  was close to significant ( $p < 0.06$ ).



**Figure 3.6 Levels of Aβ and Iso-Asp7 Aβ Were Reversed Between Groups.**

Plasma levels of Aβ and iso-Asp7 Aβ were reversed between disease group and Aβ form. For example, Aβ40 was lower than Aβ42 in the control group; however iso-Asp7 Aβ40 was higher than iso-Asp7 Aβ42 in the control group. A similar effect was present in the AD cases. Using a simple sign test, we evaluated this change. The change in direction in the Aβ40 values trended towards significance ( $p < 0.12$ ). The direction change for the Aβ42 values was significant ( $p < 0.02$ ).

## CHAPTER 4: DISCUSSION

We found significant quantities of higher order A $\beta$  multimers (oligomeric A $\beta$ ) in the neocortex that increased with disease progression, and these were considerably less abundant in the cerebellum. Similarly, PiB binding, thought to mostly reflect A $\beta$  in a fibrillar state, was increased in the SMTG but not in the cerebellum. However, in later stage AD, the amount of aggregated A $\beta$  was similar between the SMTG and cerebellum. This implies that at least some higher order A $\beta$  structures do not form solely in a concentration dependent manner, and that other processes must be involved. Differences between the amounts of oligomeric A $\beta$  in the neocortex and the cerebellum are well known (Klein, 2002; Lambert et al., 2001), and the role of these species in AD neuropathology has been explored in some detail in recent years (McDonald et al., 2010; Walsh et al., 2002). Interestingly, we found correlations between PiB binding and oligomeric, SDS- and FA-soluble A $\beta$  in the SMTG but not in the cerebellum. This further indicates that the A $\beta$  deposited in the cerebellum is different from the A $\beta$  deposited in the neocortex in some fundamental way, and that the diffuse amyloid deposits in the cerebellum are not strongly related to PiB binding.

There are both high (nM) and low ( $\mu$ M) affinity PiB binding sites on synthetic and biological A $\beta$  fibrils (Klunk et al., 2005). The low affinity site is more abundant in synthetic fibrils, fibrillar A $\beta$  from transgenic mice, and the A $\beta$  found in the brains of aged non-human primates (Maeda et al., 2007; Rosen et al., 2011). A large proportion of the PiB binding under our assay conditions (1 nM  $^3$ H-PiB) is to the high affinity site (Klunk et al., 2005). It is possible that these differences between the SMTG and cerebellum reflect an underlying difference in the disease process that could be useful in elucidating unknown, or at least unappreciated, aspects of AD. At a minimum, a comparison between the cerebellum and a neocortical region such as the SMTG

might be ideal for determining the molecular identity of the high density, high affinity PiB binding site in the AD brain. The identification and mapping of this site could represent an important step towards the development of new imaging agents.

Autopsy studies of patients subject to PiB neuroimaging are still relatively uncommon (Ikonomic et al., 2008; Klunk et al., 2005; Svedberg et al., 2009), and there has been relatively little examination of earlier stage cases of disease of the type reported here. The longitudinal study of these individuals, and the integration of PiB neuroimaging data with established pathologies and other potential biomarkers, will be critical for developing a reliable clinical protocol for AD diagnosis and monitoring (Apostolova et al., 2010). It is intriguing that our data show that PiB may have some benefit in distinguishing MCI cases from not only normal elderly controls, but possibly from preclinical AD cases as well. We emphasize that this is a study in a relatively small number of cases, and demonstrating the true utility of PiB binding as an agent for identifying MCI will require a much larger cohort. These findings are particularly important given the recommendations from the National Institute of Aging (NIA) /Alzheimer's Association which focus on the use of imaging and CSF measures to define MCI (Albert et al., 2011). These recommendations emphasize the use of subjects from longitudinal studies and incorporation of CSF and/or imaging studies to define MCI as being caused by AD pathology. Similarly, both imaging and CSF play a larger role in the defining of AD in the NIA guidelines (Jack et al., 2011). Data from the present study contribute to both of these efforts by demonstrating the utility of imaging probes for both clinical imaging as well as *ex vivo* analysis in the laboratory setting to understand the pathological processes involved in AD. This has the potential to not only advance our understanding of the disease at the molecular level, but could also lead to better imaging reagents in the future.

In the second case set, we detected an approximate 11-fold elevation in extractable A $\beta$  in the AD brain relative to controls, compared to more modest increases in the amount of PiB binding (~4 fold). We did not detect a robust elevation in oligomeric A $\beta$  using the single site immunoassay method in this study. While these data do not rule out the possibility that oligomeric and fibrillar A $\beta$  contribute to AD (Mc Donald et al., 2010; Walsh et al., 2002), they do indicate that any role these two species play in mediating AD pathogenesis occurs in the background of a tremendous amount of A $\beta$  in other pools. It is possible that oligomeric and fibrillar species of A $\beta$  contribute to AD via their synergy with other A $\beta$  pools. It is also possible that the largest contribution of oligomeric A $\beta$  to neuronal dysfunction and degeneration is of far greater importance earlier in the disease process (such as in preclinical AD (Price et al., 2009) or in cases of amnesic MCI (Petersen et al., 1999)). Alternatively, the location or local concentration of oligomeric species may be the key to their ability to promote disease onset and progression. Finally, the immunoassay approach that we used in this case series detects only relatively large forms of oligomeric A $\beta$ ; it is likely that smaller forms of oligomeric A $\beta$  (e.g., dimers, trimers, etc.) escape detection by this method. It is possible that these smaller forms of oligomeric A $\beta$  may be more important for the disease process (Walsh & Selkoe, 2004). Nevertheless, the lack of a clear increase in oligomeric A $\beta$  in AD cases highlights that, in spite of recent advances, there are still limitations on our understanding of the disease process. It is noteworthy that PiB binding in the postmortem brain was unable to discriminate between cases and controls as well as SDS soluble A $\beta$ . Postmortem PiB binding is evaluated under highly favorable experimental conditions, while binding *in vivo* occurs under less optimal conditions. Blood flow and sequestration on the time scale of the imaging session are significant *in vivo*



variables, whereas PiB has greater access to amyloid binding sites *ex vivo*. It is well known that there is considerable variability and heterogeneity in PiB retention in the human brain, with PiB retention increasing in a non-linear manner during the progression of disease and unable to uniformly discriminate AD from non-AD cases (Sojkova & Resnick, 2011). Postmortem PiB binding appears to involve only a small fraction of the total amount of A $\beta$  in the brain, and it is likely that some portion of the unlabeled amyloid is significant to the disease process (Svedberg et al., 2009). It is also likely that differentially soluble pools of A $\beta$  in the brain deposit at different rates (Murphy & LeVine, 2010), and it is unclear which of these pools PiB retention represents. The study of PiB binding *ex vivo* could shed light on these issues. Although these data do not diminish the potential clinical utility of PiB as an agent for detecting the deposition of A $\beta$  in the brain of living patients, they nevertheless raise the possibility that *in vivo* imaging using PiB is largely detecting deposits of A $\beta$  that are considered by neuropathologists as less important to the AD clinical phenotype than either NPs or NFTs. For instance, in this study and many others, the strongest relationship between MMSE and neuropathology is with neocortical NFTs (Nelson et al., 2010; Nelson et al., 2007), which are not related to the amount of PiB binding. This finding is in line with some of the earliest studies of PiB *in vivo*, which reported no relationship between PiB binding and MMSE scores (Klunk et al., 2004). However, recent work in defining the preclinical state of AD has raised the intriguing possibility that DPs are being overly discounted as a factor in pathology (Price et al., 2009). There are currently relatively few individuals that have come to autopsy following PiB neuroimaging. Further study of these individuals, and integration with other biomarker data (Apostolova et al., 2010), will be essential for developing a reliable clinical screening procedure for the detection of AD and monitoring its progression.

We were able to measure levels of A $\beta$ 40, A $\beta$ 42, iso-Asp7 A $\beta$ 40, and iso-Asp7 A $\beta$ 42 in plasma samples from AD and control cases. When standardized to the group average, AD cases had lower levels of all forms of A $\beta$ . Although the trend was convincing, this did not reach significance. The difference in iso-Asp7 A $\beta$ 40 between AD and control cases was closest to reaching significance ( $p < 0.06$ ). A $\beta$  deposition in diffuse and neuritic plaques are a hallmark of AD pathology. AD cases have significantly higher levels of A $\beta$  in the brain compared to control cases (Figure 3.1). Iso-Asp7 A $\beta$  is significantly deposited within A $\beta$  plaques in AD brain (Roher et al., 1993). With this in mind, we expected to find higher levels of A $\beta$  overall, and of iso-Asp7 A $\beta$  in particular, in the plasma from AD cases compared to control cases. However, this was not the case. A possible explanation is that once A $\beta$  plaques develop to the point of becoming neuritic, both the non-isomerized A $\beta$  and iso-Asp7 A $\beta$  peptides may be selectively sequestered within those plaques of the AD brain, and become less free to move about the periphery. If this is indeed the case, the significantly lower plaque burden among control cases could allow for more free-floating A $\beta$  species throughout the periphery, resulting in the relatively higher levels of plasma A $\beta$  seen in this study. If the trend we saw in plasma A $\beta$  levels between AD and control cases were to hold true, we would expect the effect to reach significance with a larger case study. A follow-up study is required, however, these initial data are a promising step towards utilizing aged iso-Asp7 A $\beta$  plasma levels as a potential biomarker to indicate disease state.

## Appendix I: List of Abbreviations

AC	antigen capture buffer
AD	Alzheimer's disease
AICD	amyloid precursor protein intracellular domain
APP	amyloid precursor protein
A $\beta$	amyloid-beta
C	Celsius
CCP	classical complement pathway
CON	control
CTF- $\alpha$	c-terminal fragment $\alpha$
CTF- $\beta$	c-terminal fragment $\beta$
DB	detection buffer
DP	diffuse plaque
ELISA	enzyme-linked immunosorbent assay
F/M	female/male
FA	formic acid
FTD	frontotemporal dementia
Iso-Asp7 A $\beta$	isomerized aspartate 7 amyloid-beta
MCI	mild cognitive impairment
NFT	neurofibrillary tangle
NP	neuritic plaque
OD	optical density
PBS	phosphate buffered saline

PBST	phosphate buffered saline with tween-20
PCAD	pre-clinical Alzheimer's disease
PiB	Pittsburgh binding compound B
PIC	protease inhibitor cocktail
PMI	postmortem interval
sAPP $\alpha$	secreted amyloid precursor protein alpha
sAPP $\beta$	secreted amyloid precursor protein beta
SDS	sodium dodecyl sulfate
SMTG	superior and mid temporal gyrus
TMB	3,3',5,5'-tetramethylbenzidine
TP	tris phosphate buffer

**Appendix II: A $\beta$  Sequences**

<b>A<math>\beta</math>40</b>	<b>DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV</b>
<b>A<math>\beta</math>42</b>	<b>DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA</b>
<b>Iso-Asp7 A<math>\beta</math>40</b>	<b>DAEFRH-isoD-SGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA</b>
<b>Iso-Asp7 A<math>\beta</math>42</b>	<b>DAEFRH-isoD-SGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA</b>

## References

- Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., . . . Smith, S. O. (2010). Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. *Nat Struct Mol Biol*, 17(5), 561-567. doi: 10.1038/nsmb.1799
- Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., . . . Klunk, W. E. (2008). Frequent amyloid deposition without significant cognitive impairment among the elderly. *Arch Neurol*, 65(11), 1509-1517. doi: 10.1001/archneur.65.11.1509
- Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., . . . Phelps, C. H. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*, 7(3), 270-279. doi: 10.1016/j.jalz.2011.03.008
- Apostolova, L. G., Hwang, K. S., Andrawis, J. P., Green, A. E., Babakchanian, S., Morra, J. H., . . . Alzheimer's Disease Neuroimaging, I. (2010). 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. *Neurobiol Aging*, 31(8), 1284-1303. doi: 10.1016/j.neurobiolaging.2010.05.003
- Bacsikai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., . . . Growdon, J. H. (2007). Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. *Arch Neurol*, 64(3), 431-434. doi: 10.1001/archneur.64.3.431
- Beckett, T. L., Niedowicz, D. M., Studzinski, C. M., Weidner, A. M., Webb, R. L., Holler, C. J., . . . Murphy, M. P. (2010). Effects of nonsteroidal anti-inflammatory drugs on amyloid-beta pathology in mouse skeletal muscle. *Neurobiol Dis*, 39(3), 449-456. doi: 10.1016/j.nbd.2010.05.018
- Beckett, T. L., Webb, R. L., Niedowicz, D. M., Holler, C. J., Matveev, S., Baig, I., . . . Murphy, M. P. (2012). Postmortem Pittsburgh Compound B (PIB) binding increases with Alzheimer's disease progression. *J Alzheimers Dis*, 32(1), 127-138. doi: 10.3233/JAD-2012-120655
- Braak, H., & Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*, 82(4), 239-259.
- Cairns, N. J., Bigio, E. H., Mackenzie, I. R., Neumann, M., Lee, V. M., Hatanpaa, K. J., . . . Consortium for Frontotemporal Lobar, D. (2007). Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. *Acta Neuropathol*, 114(1), 5-22. doi: 10.1007/s00401-007-0237-2
- Chondrogianni, N., Petropoulos, I., Grimm, S., Georgila, K., Catalgol, B., Friguet, B., . . . Gonos, E. S. (2014). Protein damage, repair and proteolysis. *Mol Aspects Med*, 35, 1-71. doi: 10.1016/j.mam.2012.09.001

- Cipriani, G., Dolciotti, C., Picchi, L., & Bonuccelli, U. (2011). Alzheimer and his disease: a brief history. *Neurol Sci*, 32(2), 275-279. doi: 10.1007/s10072-010-0454-7
- Das, P., Howard, V., Loosbrock, N., Dickson, D., Murphy, M. P., & Golde, T. E. (2003). Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. *J Neurosci*, 23(24), 8532-8538.
- Ewers, M., Insel, P., Jagust, W. J., Shaw, L., Trojanowski, J. Q., Aisen, P., . . . Alzheimer's Disease Neuroimaging, I. (2012). CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. *Cereb Cortex*, 22(9), 1993-2004. doi: 10.1093/cercor/bhr271
- Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., . . . Alzheimer's Disease, I. (2005). Global prevalence of dementia: a Delphi consensus study. *Lancet*, 366(9503), 2112-2117. doi: 10.1016/S0140-6736(05)67889-0
- Fonseca, M. I., Head, E., Velazquez, P., Cotman, C. W., & Tenner, A. J. (1999). The presence of isoaspartic acid in beta-amyloid plaques indicates plaque age. *Exp Neurol*, 157(2), 277-288. doi: 10.1006/exnr.1999.7058
- Grimmer, T., Henriksen, G., Wester, H. J., Forstl, H., Klunk, W. E., Mathis, C. A., . . . Drzezga, A. (2009). Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. *Neurobiol Aging*, 30(12), 1902-1909. doi: 10.1016/j.neurobiolaging.2008.01.016
- Hardy, J. A., & Higgins, G. A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. *Science*, 256(5054), 184-185.
- Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., . . . Montine, T. J. (2012). National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. *Alzheimers Dement*, 8(1), 1-13. doi: 10.1016/j.jalz.2011.10.007
- Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., . . . DeKosky, S. T. (2008). Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. *Brain*, 131(Pt 6), 1630-1645. doi: 10.1093/brain/awn016
- Jack, C. R., Jr., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., . . . Phelps, C. H. (2011). Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*, 7(3), 257-262. doi: 10.1016/j.jalz.2011.03.004
- Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., . . . Alzheimer's Disease Neuroimaging, I. (2009). Relationships between biomarkers in aging and dementia. *Neurology*, 73(15), 1193-1199. doi: 10.1212/WNL.0b013e3181bc010c

- Kemppainen, N. M., Aalto, S., Wilson, I. A., Nagren, K., Helin, S., Bruck, A., . . . Rinne, J. O. (2007). PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. *Neurology*, *68*(19), 1603-1606. doi: 10.1212/01.wnl.0000260969.94695.56
- Klein, W. L. (2002). Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. *Neurochem Int*, *41*(5), 345-352.
- Klunk, W. E. (2011). Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. *Neurobiol Aging*, *32 Suppl 1*, S20-36. doi: 10.1016/j.neurobiolaging.2011.09.006
- Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., . . . Langstrom, B. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann Neurol*, *55*(3), 306-319. doi: 10.1002/ana.20009
- Klunk, W. E., Lopresti, B. J., Ikonovic, M. D., Lefterov, I. M., Koldamova, R. P., Abrahamson, E. E., . . . Mathis, C. A. (2005). Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. *J Neurosci*, *25*(46), 10598-10606. doi: 10.1523/JNEUROSCI.2990-05.2005
- Klunk, W. E., Wang, Y., Huang, G. F., Debnath, M. L., Holt, D. P., Shao, L., . . . Mathis, C. A. (2003). The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. *J Neurosci*, *23*(6), 2086-2092.
- Koivunen, J., Scheinin, N., Virta, J. R., Aalto, S., Vahlberg, T., Nagren, K., . . . Rinne, J. O. (2011). Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. *Neurology*, *76*(12), 1085-1090. doi: 10.1212/WNL.0b013e318212015e
- Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., . . . Klein, W. L. (2001). Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. *J Neurochem*, *79*(3), 595-605.
- Leinonen, V., Alafuzoff, I., Aalto, S., Suotunen, T., Savolainen, S., Nagren, K., . . . Rinne, J. O. (2008). Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. *Arch Neurol*, *65*(10), 1304-1309. doi: 10.1001/archneur.65.10.noc80013
- Maeda, J., Ji, B., Irie, T., Tomiyama, T., Maruyama, M., Okauchi, T., . . . Sahara, T. (2007). Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. *J Neurosci*, *27*(41), 10957-10968. doi: 10.1523/JNEUROSCI.0673-07.2007
- Markesbery, W. R., Schmitt, F. A., Kryscio, R. J., Davis, D. G., Smith, C. D., & Wekstein, D. R. (2006). Neuropathologic substrate of mild cognitive impairment. *Arch Neurol*, *63*(1), 38-46. doi: 10.1001/archneur.63.1.38



- Mc Donald, J. M., Savva, G. M., Brayne, C., Welzel, A. T., Forster, G., Shankar, G. M., . . . Ageing, S. (2010). The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. *Brain*, *133*(Pt 5), 1328-1341. doi: 10.1093/brain/awq065
- McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., . . . Golde, T. (2005). Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. *Neuron*, *47*(2), 191-199. doi: 10.1016/j.neuron.2005.06.030
- Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., . . . Mintun, M. A. (2009). Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. *Arch Neurol*, *66*(12), 1469-1475. doi: 10.1001/archneurol.2009.269
- Murphy, M. P., Beckett, T. L., Ding, Q., Patel, E., Markesbery, W. R., St Clair, D. K., . . . Keller, J. N. (2007). Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. *Neurobiol Dis*, *27*(3), 301-311. doi: 10.1016/j.nbd.2007.06.002
- Murphy, M. P., & LeVine, H., 3rd. (2010). Alzheimer's disease and the amyloid-beta peptide. *J Alzheimers Dis*, *19*(1), 311-323. doi: 10.3233/JAD-2010-1221
- Nelson, P. T., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Jicha, G. A., Smith, C. D., . . . Markesbery, W. R. (2010). Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. *Brain Pathol*, *20*(1), 66-79. doi: 10.1111/j.1750-3639.2008.00244.x
- Nelson, P. T., Jicha, G. A., Schmitt, F. A., Liu, H., Davis, D. G., Mendiondo, M. S., . . . Markesbery, W. R. (2007). Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. *J Neuropathol Exp Neurol*, *66*(12), 1136-1146. doi: 10.1097/nen.0b013e31815c5efb
- O'Brien, R. J., & Wong, P. C. (2011). Amyloid precursor protein processing and Alzheimer's disease. *Annu Rev Neurosci*, *34*, 185-204. doi: 10.1146/annurev-neuro-061010-113613
- Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. *J Intern Med*, *256*(3), 183-194. doi: 10.1111/j.1365-2796.2004.01388.x
- Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., . . . Weiner, M. W. (2010). Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology*, *74*(3), 201-209. doi: 10.1212/WNL.0b013e3181cb3e25
- Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., . . . Winblad, B. (2001). Current concepts in mild cognitive impairment. *Arch Neurol*, *58*(12), 1985-1992.
- Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol*, *56*(3), 303-308.

- Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., . . . Rowe, C. C. (2007). Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. *Brain*, *130*(Pt 11), 2837-2844. doi: 10.1093/brain/awm238
- Price, J. L., McKeel, D. W., Jr., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., . . . Morris, J. C. (2009). Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. *Neurobiol Aging*, *30*(7), 1026-1036. doi: 10.1016/j.neurobiolaging.2009.04.002
- Reissner, K. J., & Aswad, D. W. (2003). Deamidation and isoaspartate formation in proteins: unwanted alterations or surreptitious signals? *Cell Mol Life Sci*, *60*(7), 1281-1295. doi: 10.1007/s00018-003-2287-5
- Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., Cotter, R. J., . . . et al. (1993). Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. *J Biol Chem*, *268*(5), 3072-3083.
- Rosen, R. F., Walker, L. C., & Levine, H., 3rd. (2011). PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. *Neurobiol Aging*, *32*(2), 223-234. doi: 10.1016/j.neurobiolaging.2009.02.011
- Schmitt, F. A., Davis, D. G., Wekstein, D. R., Smith, C. D., Ashford, J. W., & Markesbery, W. R. (2000). "Preclinical" AD revisited: neuropathology of cognitively normal older adults. *Neurology*, *55*(3), 370-376.
- Shimizu, T., Matsuoka, Y., & Shirasawa, T. (2005). Biological significance of isoaspartate and its repair system. *Biol Pharm Bull*, *28*(9), 1590-1596.
- Shimizu, T., Watanabe, A., Ogawara, M., Mori, H., & Shirasawa, T. (2000). Isoaspartate formation and neurodegeneration in Alzheimer's disease. *Arch Biochem Biophys*, *381*(2), 225-234. doi: 10.1006/abbi.2000.1955
- Sojkova, J., & Resnick, S. M. (2011). In vivo human amyloid imaging. *Curr Alzheimer Res*, *8*(4), 366-372.
- Svedberg, M. M., Hall, H., Hellstrom-Lindahl, E., Estrada, S., Guan, Z., Nordberg, A., & Langstrom, B. (2009). [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. *Neurochem Int*, *54*(5-6), 347-357. doi: 10.1016/j.neuint.2008.12.016
- Trojanowski, J. Q., Vandeerstichele, H., Korecka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., . . . Alzheimer's Disease Neuroimaging, I. (2010). Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. *Alzheimers Dement*, *6*(3), 230-238. doi: 10.1016/j.jalz.2010.03.008

- Velazquez, P., Cribbs, D. H., Poulos, T. L., & Tenner, A. J. (1997). Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. *Nat Med*, *3*(1), 77-79.
- Villemagne, V. L., Pike, K. E., Darby, D., Maruff, P., Savage, G., Ng, S., . . . Rowe, C. C. (2008). Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. *Neuropsychologia*, *46*(6), 1688-1697. doi: 10.1016/j.neuropsychologia.2008.02.008
- Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., . . . Selkoe, D. J. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature*, *416*(6880), 535-539. doi: 10.1038/416535a
- Walsh, D. M., & Selkoe, D. J. (2004). Deciphering the molecular basis of memory failure in Alzheimer's disease. *Neuron*, *44*(1), 181-193. doi: 10.1016/j.neuron.2004.09.010
- Wang, Y., Klunk, W. E., Debnath, M. L., Huang, G. F., Holt, D. P., Shao, L., & Mathis, C. A. (2004). Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease. *J Mol Neurosci*, *24*(1), 55-62. doi: 10.1385/JMN:24:1:055
- Weidner, A. M., Bradley, M. A., Beckett, T. L., Niedowicz, D. M., Dowling, A. L., Matveev, S. V., . . . Murphy, M. P. (2011). RNA oxidation adducts 8-OHG and 8-OHA change with Abeta42 levels in late-stage Alzheimer's disease. *PLoS One*, *6*(9), e24930. doi: 10.1371/journal.pone.0024930

## Vita

**Name:** Christina (Tina) Lisa Beckett  
**Birthplace:** North York, Ontario, Canada

### EDUCATION:

1994-2000 University of Toronto  
Honours Bachelor of Science in Neuroscience and Biology  
Toronto, ON, Canada

### POSITIONS HELD:

2014-2016 Staff Scientist III, University of Kentucky, Lexington, KY  
2008-2014 Research Analyst, Pr., University of Kentucky, Lexington, KY  
2007-2008 Research Analyst, University of Kentucky, Lexington, KY  
2005-2007 Laboratory Technician, Sr., University of Kentucky, Lexington, KY  
2004-2005 Veterinary Technician, McGilvray Veterinary Hospital, Toronto, Canada  
2002-2004 Manager, Folly, Toronto, Canada  
2000-2002 Veterinary Assistant, Wychwood Animal Hospital, Toronto, Canada

### PUBLICATIONS:

1. Lovell MA, Lynn BC, Fister S, Bradley-Whitman M, Murphy MP, **Beckett TL**, Norris CM (2016). A novel small molecule modulator of amyloid pathology. *J Alz Dis*, **in press**.
2. Platt TL, **Beckett TL**, Kohler K, Niedowicz DM, Murphy MP (2015). Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease. *Neuroscience*, Feb 19;315:162-74.
3. Wilcock DM, Hurban J, Helman AM, Sudduth TL, McCarty KL, **Beckett TL**, Ferrell JC, Murphy MP, Abner EL, Schmitt FA, Head E (2015). Down syndrome individuals with Alzheimer's

- disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease. *Neurobiol Aging*, 2015 Sep;36(9):2468-74.
4. Sethi M, Joshi SS, Webb RL, **Beckett TL**, Donohue KD, Murphy MP, O'Hara BF, Duncan MJ (2015). Increased fragmentation of sleep-wake cycles in the 5XFAD mouse model of Alzheimer's disease. *Neuroscience*, 2015 Apr 2;290:80-9.
  5. Holler CJ, Davis PR, **Beckett TL**, Platt TL, Webb RL, Head E, Murphy MP (2014). Bridging Integrator 1 (BIN1) protein expression increases in the Alzheimer's disease brain and correlates with neurofibrillary tangle pathology. *J Alz Dis*, 2014;42(4):1221-7.
  6. Martin SB, Dowling ALS, Lianekhammy J, Lott IT, Doran E, Murphy MP, **Beckett TL**, Schmitt FA, Head E (2014). Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease. *J Alz Dis*, 2014;42(3):767-75.
  7. Niedowicz DM, Reeves VL, Platt TL, Kohler K, **Beckett TL**, Powell DK, Lee TL, Sexton TR, Song E, Brewer LD, Latimer CS, Kraner SD, Larson KL, Ozcan S, Norris CM, Hersh LB, Porter NM, Wilcock DM, Murphy MP (2014). Obesity and diabetes cause cognitive dysfunction in the absence of accelerated beta-amyloid deposition in a murine model of mixed or vascular dementia. *Acta Neuropathol Commun*, 2014 Jun 10;2:64.
  8. Bradley-Whitman MA, Timmons MD, **Beckett TL**, Murphy MP, Lynn BC, Lovell MA (2013). Nucleic acid oxidation: an early feature of Alzheimer's disease. *J Neurochem*, 2014 Jan;128(2):294-304.
  9. Hardas SS, Sultana R, Clark AM, **Beckett TL**, Szweda Li, Murphy MP, Butterfield DA (2013). Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. *Redox Biol*, 2013 Jan 30;1(1):80-5.
  10. **Beckett TL**, Studzinski CM, Keller JN, Paul Murphy M, Niedowicz DM (2013). A ketogenic diet improves motor performance but does not affect  $\beta$ -amyloid levels in a mouse model of Alzheimer's disease. *Brain Res*, 2013 Apr 10;1505:61-7.
  11. Zhang L, Dasuri K, Fernandez-Kim SO, Bruce-Keller AJ, Freeman LR, Pepping JK, LeVine H 3<sup>rd</sup>, **Beckett TL**, Murphy MP, Keller JN (2013). Prolonged diet induced obesity has minimal effects towards brain pathology in a mouse model of cerebral amyloid angiopathy: implications for studying obesity-brain interactions in mice. *Biochim Biophys Acta*, 2013 Sep;1832(9):1456-62.

12. Niedowicz DM, Studzinski CM, Weidner AM, Platt TL, Kingry KN, **Beckett TL**, Bruce-Keller AJ, Keller JN, Murphy MP (2013). Leptin regulates amyloid  $\beta$  production via the  $\gamma$ -secretase complex. *Biochim Biophys Acta*, 2013 Mar; 1832(3):439-44.
13. Head E, Murphey HL, Dowling ALS, McCarty KL, Bethel SR, Nitz JA, Pleiss M, Vanrooyen J, Grossheim M, Smiley JR, Murphy MP, **Beckett TL**, Pagani D, Bresch F, Hendrix C (2012). A combination cocktail improves spatial attention in a canine model of human aging and Alzheimer's disease. *J Alz Dis*, 2012;32(4): 1029-42.
14. **Beckett TL\***, Webb RL\*, Niedowicz DM\*, Holler CJ, Matveev S, Baig I, LeVine H 3<sup>rd</sup>, Keller JN, Murphy MP (2012). Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression. *J Alz Dis*, 2012 Jan 1;32(1):127-38. **\*co-first author**
15. Niedowicz DM\*, **Beckett TL\***, Matveev S, Weidner AM, Baig I, Kryscio RJ, Mendiondo MS, LeVine H 3<sup>rd</sup>, Keller JN, Murphy MP (2012). Pittsburgh Compound B and the postmortem diagnosis of Alzheimer disease. *Ann Neurol*, 2012 Oct; 72(4):564-70. **\*co-first author**
16. Furman JL, Sama DM, Gant JC, **Beckett TL**, Murphy MP, Bachstetter AD, Van Eldik LJ, Norris C (2012). Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. *J Neurosci*, 2012 Nov 14;32(46):16129-40.
17. Jayaraman A, Carroll JC, Morgan TE, Lin S, Zhao L, Arimoto JM, Murphy MP, **Beckett TL**, Finch CE, Brinton RD, Pike CJ (2012). 17 $\beta$ -estradiol and progesterone regulate expression of  $\beta$ -amyloid clearance factors in primary neuron cultures and female rat brain. *Endocrinology*, 2012 Nov;152(11):5467-79.
18. Duncan MJ, Smith JT, Franklin KM, **Beckett TL**, Murphy MP, St Clair DK, Donohue KD, Striz M, O'Hara BF (2012). Effects of aging and genotype on circadian rhythms, sleep, and clock gene expression in APPxPS1 knock-in mice, a model for Alzheimer's disease. *Exp Neurol*, 2012 Aug;236(2):249-58.
19. Searcy JL, Phelps JT, Pancani T, Kadish I, Popovic J, Anderson KL, **Beckett TL**, Murphy MP, Chen KC, Blalock EM, Landfield PW, Porter NM, Thibault O (2012). Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. *J Alz Dis*, 2012;30(4):943-61.
20. Holler CJ, Webb RL, Laux AL, **Beckett TL**, Niedowicz DM, Ahmed RR, Liu Y, Simmons CR, Dowling AL, Spinelli A, Khurgel M, Estus S, Head E, Hersh LB, Murphy MP (2011). BACE2

- expression increases in human neurodegenerative disease. *Am J Pathol*, 2012 Jan;180(1):337-50.
21. Cenini G, Dowling AL, **Beckett TL**, Barone E, Mancuso C, Murphy MP, Levine H 3<sup>rd</sup>, Lott IT, Schmitt FA, Butterfield DA, Head E (2011). Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. *Biochim Biophys Acta*, 2012 Feb;1822(2):130-8.
  22. Weidner AM\*, Bradley MA\*, **Beckett TL\***, Niedowicz DM, Dowling AL, Matveev SV, Levine H 3<sup>rd</sup>, Lovell MA, Murphy MP (2011). RNA oxidation adducts 8-OHG and 8-OHA change with A $\beta$ 42 levels in late-stage Alzheimer's disease. *PLoS One*, 2011;6(9):e24930. **\*co-first author**
  23. Bruce-Keller AJ, Gupta S, Knight AG, **Beckett TL**, McMullen JM, Davis PR, Murphy MP, Van Eldik LJ, St Clair D, Keller JN (2011). Cognitive impairment in humanized APPxPS1 mice is linked to A $\beta$ (1-42) and NOX activation. *Neurobiol Dis*, 2011 Dec;44(3):317-26.
  24. Murphy MP, Morales J, **Beckett TL**, Astarita G, Piomelli D, Weidner A, Studzinski CM, Dowling ALS, Wang X, Levine H, Kryscio RJ, Lin Y, Barrett E, Head E (2010). Changes in cognition and A $\beta$  processing with long term cholesterol reduction using atorvastatin in aged dogs. *J Alz Dis*, 2010;22(1): 135-50. Erratum in: *J Alzheimers Dis*. 2011 Jan 1;24(4):837.
  25. Niedowicz DM, **Beckett TL**, Holler CJ, Weidner AM, Murphy MP (2010). APP(DeltaNL695) expression in murine tissue downregulates CNBP expression. *Neurosci Lett*, 2010 Sep 20;482(1):57-61.
  26. Liu Y, Studzinski CM, **Beckett TL**, Murphy MP, Klein R, Hersh LB (2010). Circulating neprilysin clears brain amyloid. *Mol Cell Neurosci*, 2010 Oct;45(2):101-7.
  27. **Beckett TL**, Niedowicz DM, Studzinski CM, Weidner AM, Webb RL, Holler CJ, Ahmed RR, Levine H 3<sup>rd</sup>, Murphy MP (2010). Effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on amyloid-beta pathology in mouse skeletal muscle. *Neurobiol Dis*, 2010 Sep;39(3):229-56.
  28. Aluise CD, Robinson RS, **Beckett TL**, Murphy MP, Cai J, Pierce WD, Markesbery WR, Butterfield DA (2010). Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide & proteomics. *Neurobiol Dis*. 2010 Aug;39(2):221-8.
  29. Webb RL, Findlay KA, Green MA, **Beckett TL**, Murphy MP (2010). Efficient activation of reconstructed rat embryos by cyclin-dependent kinase inhibitors. *PLoS One*. 2010 Mar 19;5(3):e9799.

30. Head E, Pop V, Sarsoza F, Kahed R, **Beckett TL**, Studzinski CM, Tomic JL, Glabe CG, Murphy MP (2009). Amyloid  $\beta$ -peptide and oligomers in the brain and cerebrospinal fluid of aged canines. *J Alz Dis*, 2010;20(2):637-46.
31. Ahmed RR, Holler CJ, Webb RL, Li F, **Beckett TL**, Murphy MP (2009). BACE1 and BACE2 enzymatic activities in Alzheimer's disease. *J Neurochem*, 2010 Feb;112(4):1045-53.
32. Murphy MP, Ahmed RR, Webb RL, Holler CJ, Li F, **Beckett TL**, Niedowicz DM, Studzinski CM, Head E (2009). Aging, Neurodegenerative Disease and  $\beta$ -Secretase. In: *Proceedings of the 9<sup>th</sup> International Conference on AD/PD*; Prague, Czech Republic.
33. Rosario ER, Chang L, **Beckett TL**, Carroll JC, Murphy MP, Stanczyk FZ, Pike CJ (2009). Age-related changes in serum and brain levels of androgens in male Brown Norway rats. *Neuroreport*, 2009 Nov 25;20: 1534-37.
34. Abdul HM, Sama MA, Furman JL, Mathis DM, **Beckett TL**, Weidner AM, Patel ES, Baig I, Murphy MP, Levine H, Kraner SD, Norris CM (2009). Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. *J Neurosci*, 2009 Oct 14;29(41):12957-69.
35. Liu Y, Studzinski C, **Beckett T**, Guan H, Hersh MA, Murphy MP, Klein R, Hersh LB (2009). Expression of Neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. *Mol Ther*, 2009 Aug;17(8): 1381-6.
36. Studzinski CM, MacKay WA, **Beckett TL**, Henderson ST, Murphy MP, Sullivan PG, Burnham WM. Induction of ketosis may improve mitochondrial function and decrease steady-state amyloid- $\beta$  precursor protein (APP) levels in the aged dog (2008). *Brain Res*, 2008 Aug 21;1226:209-17.
37. Liu Y, Guan H, **Beckett TL**, Juliano MA, Juliano L, Song ES, Chow KM, Murphy MP, Hersh LB (2007). *In vitro* and *in vivo* degradation of A $\beta$  peptide by peptidases coupled to erythrocytes. *Peptides*, 2007 Dec;28:2348-55.
38. Murphy MP, **Beckett TL**, Ding Q, Patel E, Markesbery WR, St Clair DK, LeVine H, Keller JN (2007). A $\beta$  solubility and deposition during Alzheimer's disease progression and in APPxPS-1 knock-in mice. *Neurobiol Dis*, 2007 Sep;27(3):303-11.